Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

VV330 Continuous ECG Platform, VivaLNK Adhesive Patch

K-Number: K191870 · 2020-01-07

ApplicantVivaLNK, Inc.
Decision Date2020-01-07
Product CodeDRG
Advisory CommitteeCV
DecisionSubstantially Equivalent

Device Summary

VV330 Continuous ECG Platform, VivaLNK Adhesive Patch is the device name listed in this FDA 510(k) record. The listed applicant is VivaLNK, Inc.. It received FDA 510(k) clearance on 2020-01-07 under 510(k) number K191870. The device is classified under product code DRG. It was reviewed by the CV advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the VV330 Continuous ECG Platform, VivaLNK Adhesive Patch?

VV330 Continuous ECG Platform, VivaLNK Adhesive Patch is a medical device that received FDA 510(k) clearance on 2020-01-07. The listed applicant is VivaLNK, Inc.. The 510(k) number is K191870.

When did VV330 Continuous ECG Platform, VivaLNK Adhesive Patch receive FDA 510(k) clearance?

VV330 Continuous ECG Platform, VivaLNK Adhesive Patch received FDA 510(k) clearance on 2020-01-07, under 510(k) number K191870.

Who is the listed applicant for VV330 Continuous ECG Platform, VivaLNK Adhesive Patch?

The FDA 510(k) record lists VivaLNK, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for VV330 Continuous ECG Platform, VivaLNK Adhesive Patch?

The FDA product code for VV330 Continuous ECG Platform, VivaLNK Adhesive Patch is DRG.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT04624646Clinical Implication of Atrial Fibrillation Detection Using Wearable Device in Patients With Cryptogenic StrokeACTIVE_NOT_RECRUITINGNCT05355948A Clinical Trial to Evaluate the Detection of Atrial Fibrillation for an One Day Versus More Than or Equal to Eight Days Using MEMO Patch PLUS in Individuals Aged ≥ 75 Years, or Those at High Risk of StrokeCOMPLETEDNCT06250712Hativ® ELectrocardiogram Monitoring on Patients With Suspected ArrhythmiaRECRUITINGNCT06699056AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable MonitorRECRUITINGNCT07205367Validation Study: Extended Wear Performance of the Zio Monitor - SHASTA IICOMPLETEDNCT07333547Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG PlatformRECRUITING

Other records listing VivaLNK, Inc. as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K181013Fever ScoutK162137Fever Scout™ Continuous Monitoring thermometer

Related Devices (Code: DRG)

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

K261569UbiqVue™ 2AYe Cardiac System (UX2253)Lifesignals, Inc.K252984Perin Health System (PHD80060-2)Perin Health Devices, LLCK252440EasyTeleMed (2.0.2)Ingeniars S.R.L.K250259TeleRehab Aermos Cardiopulmonary RehabilitationThe ScottCare CorporationK243837iBSMIorbit Digital Technologies Private LimitedK242018UbiqVue™ 2A Multi-parameter System (UX2550)Lifesignals, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑